

AMENDMENTS TO THE CLAIMS


In the claims, please amend claims 1, 2, 6 and 13 as follows:

1. (currently amended) ~~A compound for inserting into a mammal, comprising: the compound having a disulfide bond that is labile under mammalian physiologic conditions selected from the group consisting of (a) a disulfide bond that is cleaved more rapidly than oxidized glutathione and (b) a disulfide bond constructed from thiols in which one of the constituent thiols has a lower pKa than glutathione and wherein the compound contains a transduction signal.~~

A compound for delivering a molecule from outside a mammalian cell to the cytoplasm of said mammalian cell comprising: said molecule covalently linked to a transduction signal via an activated disulfide bond that is cleaved more rapidly than oxidized glutathione wherein said transduction signal transports said molecule to the cytoplasm of said cell and cleavage of said disulfide bond in said cell enhances delivery of said molecule to the cytoplasm of said cell.

2. (currently amended) The compound of claim 1 wherein the transduction signal consists of ~~fat~~ a peptide with sequence substantially identical to SEQ ID 1.
3. (original) The compound of claim 1 wherein the transduction signal consists of VP22.
4. (original) The compound of claim 1 wherein the transduction signal consists of ANTP.
5. (original) The compound of claim 1 wherein the transduction signal consists of a polymer containing a cationic charge.
6. (currently amended) The compound of claim 5 ~~claim 1~~ wherein the transduction signal consists of a peptide containing cationic residues.
- 7-12. (canceled)
13. (currently amended) The compound of claim 1 wherein ~~the compound~~ said molecule is associated with a nucleic acid.

Respectfully submitted,



Mark K. Johnson Reg. No. 35,909
Mirus
505 South Rosa Road
Madison, WI 53719
608-238-4400

I hereby certify that this correspondence is being sent
by facsimile transmission to: Commissioner for
Patents, PO Box 1450, Alexandria, VA 22313-1450
on this date: 6/10/04



Kirk Ekens